1186 related articles for article (PubMed ID: 24684643)
1. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
2. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
Buono JL; Mathur K; Averitt AJ; Andrae DA
J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
[TBL] [Abstract][Full Text] [Related]
3. Healthcare costs among patients with chronic constipation: a retrospective claims analysis in a commercially insured population.
Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT; Doshi JA
J Med Econ; 2014 Feb; 17(2):148-58. PubMed ID: 24168640
[TBL] [Abstract][Full Text] [Related]
4. Economic burden of inadequate symptom control among US commercially insured patients with irritable bowel syndrome with diarrhea.
Buono JL; Mathur K; Averitt AJ; Andrae DA
J Med Econ; 2017 Apr; 20(4):353-362. PubMed ID: 27919177
[TBL] [Abstract][Full Text] [Related]
5. Clinical and Economic Burden of Commercially Insured Patients with Acromegaly in the United States: A Retrospective Analysis.
Placzek H; Xu Y; Mu Y; Begelman SM; Fisher M
J Manag Care Spec Pharm; 2015 Dec; 21(12):1106-12. PubMed ID: 26679960
[TBL] [Abstract][Full Text] [Related]
6. Patients with Idiopathic Membranous Nephropathy: A Real-World Clinical and Economic Analysis of U.S. Claims Data.
Nazareth TA; Kariburyo F; Kirkemo A; Xie L; Pavlova-Wolf A; Bartels-Peculis L; Vaidya N; Sim JJ
J Manag Care Spec Pharm; 2019 Sep; 25(9):1011-1020. PubMed ID: 31283419
[TBL] [Abstract][Full Text] [Related]
7. A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation.
Nellesen D; Yee K; Chawla A; Lewis BE; Carson RT
J Manag Care Pharm; 2013; 19(9):755-64. PubMed ID: 24156644
[TBL] [Abstract][Full Text] [Related]
8. A case-control comparison of direct healthcare-provider medical costs of chronic idiopathic constipation and irritable bowel syndrome with constipation in a community-based cohort.
Herrick LM; Spalding WM; Saito YA; Moriarty J; Schleck C
J Med Econ; 2017 Mar; 20(3):273-279. PubMed ID: 27783533
[TBL] [Abstract][Full Text] [Related]
9. Variation in Care for Patients with Irritable Bowel Syndrome in the United States.
Lacy BE; Patel H; Guérin A; Dea K; Scopel JL; Alaghband R; Wu EQ; Mody R
PLoS One; 2016; 11(4):e0154258. PubMed ID: 27116612
[TBL] [Abstract][Full Text] [Related]
10. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States.
Asche CV; Singer ME; Jhaveri M; Chung H; Miller A
J Manag Care Pharm; 2010; 16(9):703-12. PubMed ID: 21067256
[TBL] [Abstract][Full Text] [Related]
11. The economic burden of treatment failure amongst patients with irritable bowel syndrome with constipation or chronic constipation: a retrospective analysis of a Medicaid population.
Guerin A; Carson RT; Lewis B; Yin D; Kaminsky M; Wu E
J Med Econ; 2014 Aug; 17(8):577-86. PubMed ID: 24811855
[TBL] [Abstract][Full Text] [Related]
12. Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data.
Margolis J; Barron JJ; Grochulski WD
J Manag Care Pharm; 2005; 11(9):727-34. PubMed ID: 16300416
[TBL] [Abstract][Full Text] [Related]
13. Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries.
Tack J; Stanghellini V; Mearin F; Yiannakou Y; Layer P; Coffin B; Simren M; Mackinnon J; Wiseman G; Marciniak A;
BMC Gastroenterol; 2019 May; 19(1):69. PubMed ID: 31064345
[TBL] [Abstract][Full Text] [Related]
14. The Economic Burden of Comorbid Obstructive Sleep Apnea Among Patients with Chronic Obstructive Pulmonary Disease.
Hong YD; Onukwugha E; Slejko JF
J Manag Care Spec Pharm; 2020 Oct; 26(10):1353-1362. PubMed ID: 32996389
[TBL] [Abstract][Full Text] [Related]
15. Medical costs and resource utilization for hemophilia patients with and without HIV or HCV infection.
Tencer T; Friedman HS; Li-McLeod J; Johnson K
J Manag Care Pharm; 2007; 13(9):790-8. PubMed ID: 18062730
[TBL] [Abstract][Full Text] [Related]
16. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population.
Blanchette CM; Gutierrez B; Ory C; Chang E; Akazawa M
J Manag Care Pharm; 2008 Mar; 14(2):176-85. PubMed ID: 18331119
[TBL] [Abstract][Full Text] [Related]
17. Costs of gastrointestinal events after outpatient opioid treatment for non-cancer pain.
Kwong WJ; Diels J; Kavanagh S
Ann Pharmacother; 2010 Apr; 44(4):630-40. PubMed ID: 20197473
[TBL] [Abstract][Full Text] [Related]
18. Disease-related and all-cause health care costs of elderly patients with gout.
Wu EQ; Patel PA; Yu AP; Mody RR; Cahill KE; Tang J; Krishnan E
J Manag Care Pharm; 2008 Mar; 14(2):164-75. PubMed ID: 18331118
[TBL] [Abstract][Full Text] [Related]
19. Incremental health care resource utilization and economic burden of venous thromboembolism recurrence from a U.S. payer perspective.
Lin J; Lingohr-Smith M; Kwong WJ
J Manag Care Pharm; 2014 Feb; 20(2):174-86. PubMed ID: 24456319
[TBL] [Abstract][Full Text] [Related]
20. All-cause and bleeding-related health care costs in warfarin-treated patients with atrial fibrillation.
Ghate SR; Biskupiak J; Ye X; Kwong WJ; Brixner DI
J Manag Care Pharm; 2011 Nov; 17(9):672-84. PubMed ID: 22050392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]